Risk compensation in HIV prevention: Implications for vaccines, microbicides, and other biomedical HIV prevention technologies
about
sameAs
Male circumcision for HIV prevention in high HIV prevalence settings: what can mathematical modelling contribute to informed decision making?Behavioral aspects of male circumcision for the prevention of HIV infectionHow Stigma Surrounding the Use of HIV Preexposure Prophylaxis Undermines Prevention and Pleasure: A Call to Destigmatize "Truvada Whores"Preparing for HIV pre-exposure prophylaxis: lessons learned from post-exposure prophylaxisAre dual-method messages undermining STI/HIV prevention?Oral pre-exposure prophylaxis (PrEP) for prevention of HIV in serodiscordant heterosexual couples in the United States: opportunities and challengesNo evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxisSelf-Consent for HIV Prevention Research Involving Sexual and Gender Minority Youth: Reducing Barriers Through Evidence-Based EthicsRelationship-level analysis of drug users' anticipated changes in risk behavior following HIV vaccinationHIV-1 Proteins Influence Novelty-Seeking Behavior and Alter Region-Specific Transcriptional Responses to Chronic Nicotine Treatment in HIV-1Tg Rats.Resilience, tipping, and hydra effects in public health: emergent collective behavior in two agent-based models.Systemic preexposure prophylaxis for HIV: translating clinical data to clinical practice.Heterosexual anal intercourse and HIV infection risks in the context of alcohol serving venues, Cape Town, South Africa."When I was circumcised I was taught certain things": risk compensation and protective sexual behavior among circumcised men in Kisumu, KenyaModeling structural, dyadic, and individual factors: the inclusion and exclusion model of HIV related behaviorPaying for prevention: challenges to health insurance coverage for biomedical HIV prevention in the United States.Study designs for identifying risk compensation behavior among users of biomedical HIV prevention technologies: balancing methodological rigor and research ethics.Decrease in sexual risk behaviours after early initiation of antiretroviral therapy: a 24-month prospective study in Côte d'Ivoire.Adherence to antiretroviral therapy and HIV transmission risks: implications for test-and-treat approaches to HIV prevention.Preexposure prophylaxis and predicted condom use among high-risk men who have sex with menEffects of messaging about multiple biomedical and behavioral HIV prevention methods on intentions to use among US MSM: results of an experimental messaging study.Development of an HIV vaccine attitudes scale to predict HIV vaccine acceptability among vulnerable populations: L.A. VOICESPre-exposure prophylaxis state of the science: empirical analogies for research and implementation.Establishing HIV treatment as prevention in the HIV Prevention Trials Network 052 randomized trial: an ethical odysseyLearning that circumcision is protective against HIV: risk compensation among men and women in Cape Town, South Africa.Ambiguity, ambivalence, and apprehensions of taking HIV-1 pre-exposure prophylaxis among male couples in San Francisco: a mixed methods study.Packaging PrEP to Prevent HIV: An Integrated Framework to Plan for Pre-Exposure Prophylaxis Implementation in Clinical PracticeOptimizing content for pre-exposure prophylaxis (PrEP) counseling for men who have sex with men: Perspectives of PrEP users and high-risk PrEP naïve men.Rethinking prevention of HIV type 1 infection.Assumed infectiousness, treatment adherence and sexual behaviours: applying the Swiss Statement on infectiousness to HIV-positive alcohol drinkers.The biobehavioral Women's Health CoOp in Pretoria, South Africa: study protocol for a cluster-randomized design"After my husband's circumcision, I know that I am safe from diseases": women's attitudes and risk perceptions towards male circumcision in Iringa, Tanzania.Prevalence of sexually transmitted co-infections in people living with HIV/AIDS: systematic review with implications for using HIV treatments for prevention.Cost effectiveness of 'on demand' HIV pre-exposure prophylaxis for non-injection drug-using men who have sex with men in CanadaSafe-sex belief and sexual risk behaviours among adolescents from three developing countries: a cross-sectional study.Targeting pre-exposure prophylaxis among men who have sex with men in the United States and Peru: partnership types, contact rates, and sexual role.Preparing for the Rollout of Pre-Exposure Prophylaxis (PrEP): A Vignette Survey to Identify Intended Sexual Behaviors among Women in Kenya and South Africa if Using PrEPAnticipated HIV Vaccine Acceptability among Sexually Active African-American Adult Women.A novel combination HIV prevention strategy: post-exposure prophylaxis with contingency management for substance abuse treatment among methamphetamine-using men who have sex with men.Motivations for Reducing Other HIV Risk-Reduction Practices if Taking Pre-Exposure Prophylaxis: Findings from a Qualitative Study Among Women in Kenya and South Africa.
P2860
Q21563397-F6137AB5-2218-4F53-A466-3FF013F717A4Q22252602-8041F737-2D48-4311-BBD9-0CF9037FAE68Q26798250-C161784A-EAC2-42E2-B4C4-F160538E3323Q26820865-D21127E1-3E24-4F54-B7CC-999031934A86Q26828575-798DA75B-9482-435B-AC1F-3EC527B92EC9Q27023352-370968C7-1139-4F72-A3E9-10168310B56AQ28537713-420C8D6A-55B4-4D71-9AF1-D35C55AC564BQ30152184-66AB7F14-4F31-4CD1-946E-011B5FFFC109Q30204590-D98D71B1-5D33-4353-BB41-95B0622E29E4Q30252876-1539017C-99F3-4A28-8D6D-4A3564FEEF8FQ30727000-31F286CD-C351-47CF-ADE9-A92F0C359961Q30744184-A716AA6C-308B-42F4-83B2-19431A1291A2Q31038944-C6888E0D-5CC3-473B-B397-989F69A9D212Q33682123-EB1A9626-253C-4770-96AA-AA870481AB0DQ33694480-73F82388-8BE7-4602-95B3-8168CEA97939Q33696533-D83E4D09-DC80-4A30-B374-89596CDF13EAQ33718608-2E65B00F-E262-461C-91CA-320F9BCEBF64Q33832234-38AF7191-1FAC-4D3E-B2D2-0FBDBBF344D6Q33874948-77999732-CFE5-4EDA-BC7C-E33747829C06Q34012348-813F13C3-9070-4374-9ECA-14510B7AC634Q34022092-5E5E12D7-4DC4-4901-BC39-58E4CDFCB31EQ34063486-88DBC839-65EC-486A-BB75-47B97D02C174Q34123592-D6211719-D0C3-4280-9C22-3E4FC49C3BD4Q34280961-4E7EA996-3E0D-4B00-ABD8-F0512DD6F85BQ34351063-DA378328-E65A-435D-8C24-2C01E28E4566Q34482984-5E9A88D4-4B24-46C8-910E-5DAD9301EB83Q34680992-B105E47F-AA49-4578-863E-827B0105F5F0Q34696493-95AA429C-E015-42E8-8454-A68E503DF1C6Q34767070-44941EEB-69C9-49EC-8236-EE918C15CAC6Q34820367-FDB8B31E-CF7C-4E95-9045-7A144D71992CQ34874557-FB4C447C-47E8-4804-8A98-A014723C2CBBQ34979865-1D1A291C-3BC4-44F2-A1A6-E52929FF9207Q35051376-B1869A4C-E826-42F1-A33E-51765F706D4EQ35158119-092B2D9C-F3E9-4E17-84D9-7E619434795FQ35573073-DD7D26BB-1384-468D-BCBA-60D2C7C0EF49Q35575958-219FA026-2C49-45BF-AE6E-205E5CE67EAFQ35657813-1FCB75CA-1DCB-4BC4-9DFE-6FDE7E2D612AQ35890620-18746B2C-2C85-4E5D-9428-1836D2279FAEQ36005091-090D0051-410D-4E62-80D8-052A78B7929BQ36006842-03A77F4B-7CA3-47D1-8374-BC03BBE79D40
P2860
Risk compensation in HIV prevention: Implications for vaccines, microbicides, and other biomedical HIV prevention technologies
description
2007 nî lūn-bûn
@nan
2007 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Risk compensation in HIV preve ...... al HIV prevention technologies
@ast
Risk compensation in HIV preve ...... al HIV prevention technologies
@en
Risk compensation in HIV preve ...... al HIV prevention technologies
@nl
type
label
Risk compensation in HIV preve ...... al HIV prevention technologies
@ast
Risk compensation in HIV preve ...... al HIV prevention technologies
@en
Risk compensation in HIV preve ...... al HIV prevention technologies
@nl
altLabel
Risk compensation in HIV preve ...... al HIV prevention technologies
@en
prefLabel
Risk compensation in HIV preve ...... al HIV prevention technologies
@ast
Risk compensation in HIV preve ...... al HIV prevention technologies
@en
Risk compensation in HIV preve ...... al HIV prevention technologies
@nl
P2860
P3181
P1476
Risk compensation in HIV preve ...... al HIV prevention technologies
@en
P2093
Lisa A. Eaton
Seth C. Kalichman
P2860
P2888
P304
P3181
P356
10.1007/S11904-007-0024-7
P407
P577
2007-11-01T00:00:00Z
2007-12-01T00:00:00Z
P5875
P6179
1048775560